论文部分内容阅读
Batroxobin是一种从蛇毒液中分离出来的与凝血酶类似的酶(分子量为360 000的糖蛋白),作用在于降低血清纤维蛋白原以促进血液循环。作者用Defibrase(batroxobin的商品名,DF)和倍他米松(BM)对168例特发性突聋患者进行配对双盲研究,分析和比较突聋患者用这两种不同药物治疗时听力恢复的过程。受试病人初诊时听力损失大于55dB HL,发病时间不超过2周,168例中,82例患者用“DF”治疗(称DF组),86例用BM治疗(称BM组)。DF组头三天每天静注10单位DF,然后改为隔天一次,持续两周。BM组口服加静注BM,剂
Batroxobin is a thrombin-like enzyme (glycoprotein with a molecular weight of 360,000) isolated from snake venom and functions to lower serum fibrinogen to promote blood circulation. The authors used a double-blind study of 168 patients with idiopathic sudden deafness using Defibrase (a commercial name for DF, batroxobin) and betamethasone (BM) to analyze and compare the hearing recovery of patients with deafness using these two different drugs process. Hearing loss was greater than 55 dB HL at initial examination, and the onset time was less than 2 weeks. Of the 168 patients, 82 were treated with DF (DF) and 86 were treated with BM (BM). The DF group intravenously administered 10 units of DF daily for the first three days and then changed to the next day for two weeks. BM group oral plus intravenous injection of BM, agent